OKYO Pharma Limited, (OKYO): Price and Financial Metrics

OKYO Pharma Limited, (OKYO): $1.49

0.01 (-0.67%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

Add OKYO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#303 of 365

in industry

OKYO Price/Volume Stats

Current price $1.49 52-week high $3.25
Prev. close $1.50 52-week low $0.92
Day low $1.45 Volume 18,600
Day high $1.52 Avg. volume 193,000
50-day MA $1.49 Dividend yield N/A
200-day MA $1.63 Market Cap 42.96M

OKYO Stock Price Chart Interactive Chart >


OKYO Pharma Limited, (OKYO) Company Bio


OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.


OKYO Latest News Stream


Event/Time News Detail
Loading, please wait...

OKYO Latest Social Stream


Loading social stream, please wait...

View Full OKYO Social Stream

Latest OKYO News From Around the Web

Below are the latest news stories about OKYO PHARMA LTD that investors may wish to consider to help them evaluate OKYO as an investment opportunity.

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Top-line Efficacy and Safety Data on Track for Release in December 2023LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce the last patient of a planned 240-patient double-blind plac

Yahoo | December 4, 2023

OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction

Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary shareSimultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, materially reducing current payables LONDON and NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), a clinical stage biopharmaceutical company developing innovative therapies for

Yahoo | October 31, 2023

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clinical trial to treat dry eye disease, with top-line data anticipated in December 2023. LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical compa

Yahoo | October 9, 2023

OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")

Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial.The dropout rate is 5.4% and unrelated to side effects. Top-line efficacy and safety data are on schedule for release in December 2023. LONDON and NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing

Yahoo | October 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | September 15, 2023

Read More 'OKYO' Stories Here

OKYO Price Returns

1-mo 4.93%
3-mo -15.82%
6-mo -19.46%
1-year -0.67%
3-year N/A
5-year N/A
YTD -15.82%
2023 -7.33%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!